Preformed cytotoxic antibodies in potential allograft recipients: recent data.
Presensitization to donor human leukocyte antigen (HLA) remains a major barrier to cell and organ transplantation, thereby contributing to patient mortality. The risks associated with transplantation in the presence of preformed antidonor HLA antibodies range from hyperacute rejection and increased frequency and severity of rejection to no appreciable effect on transplant outcome. Recent evidence has emphasized the importance of immunologic history, anti-HLA antibody class and titer, and differential organ susceptibility to antibody-mediated damage to explain differences in risk for antibody-mediated rejection. Furthermore, in studies of endothelial cells, ligation of class I molecules by subsaturating concentrations of antibodies stimulated expression of cell survival proteins, raising the possibility that, under certain conditions, antibodies promote graft accommodation providing a mechanism for the endothelium to resist immune and inflammatory damage. The discovery of capillary-bound C4d as a robust diagnostic marker for antibody-mediated rejection, coupled with the development of solid-phase assays for the identification of HLA-specific antibodies, has enhanced our ability to detect antibody-mediated rejection and interpret cross-match results. With new diagnostic tools and immunosuppression regimens such as plasmapheresis and intravenous immunoglobulin therapy targeting the humoral immune response, it is time for a concerted effort to reassess the role of alloantibodies in acute and chronic rejection.